IAPMD asks Asarina Pharma your questions about Sepranalone Clinical Trials

On May 5th 2020, IAPMD met with Asarina Pharma to ask them YOUR questions about the recent top-line results from the Phase IIb Clinical Trials of Sepranalone. Asarina Pharma are the developers of Sepranalone - the first PMDD specific treatment developed in the world. Sepranalone has been many years in the making by the team at Asarina Pharma based in Sweden.
Clinical trials for this treatment were held in 4 countries across the world - the UK, Sweden, Poland, and Germany. Recent results from the stage 2B clinical trials drew a halt to any further development for Sepranalone as a treatment for PMDD. This was due to an unexpectedly large Placebo response in the last set of clinical trials. However, this medication will continue to be developed as a treatment for menstrual migraines and Tourette's syndrome.
We asked patients for their questions about these result results and put them to Karin Ekburg, Chief Operating Officer from Asarina Pharma.
This interview was recorded on Monday 4th of May 2020 and all information is correct at time of recording. Please visit iapmd.org for further information about PMDD and other treatments available and please visit asarinapharma.com for updates on the ongoing development of Sepranalone for menstrual migraines and Tourette syndrome.